Hbvaxpro (Aluminium, Hepatitis B Surface Antigen (Rdna) [produced In S. Cerevisiae Cells By Rdna])

Hbvaxpro is indicated for the active immunization against hepatitis B virus infection in individuals who have not been previously vaccinated.

• Primary prevention in infants, children, and adults.
• Post‑exposure prophylaxis for persons with recent exposure to hepatitis B.
• Use in healthcare workers at risk of occupational exposure.
• Administration as part of a three‑dose series (0, 1, and 6 months) according to local guidelines.
• May be given to individuals with chronic liver disease to reduce risk of superinfection.

The safety profile of Hbvaxpro reflects typical reactions observed with recombinant hepatitis B vaccines.

Common

• Pain, redness, or swelling at the injection site, typically resolving within a few days.
• Low‑grade fever, usually transient and self‑limited.
• Fatigue or mild malaise lasting 24–48 hours.

Serious

• Severe allergic reaction (anaphylaxis), characterized by difficulty breathing, hives, or swelling of the face and throat.
• Guillain‑Barré syndrome, a rare autoimmune neuropathy presenting with muscle weakness.
• Persistent high fever or neurological symptoms such as weakness, numbness, or seizures, requiring immediate medical attention.

Before administering Hbvaxpro, healthcare providers should review the patient’s medical history and consider specific precautionary measures.

• Known hypersensitivity to any vaccine component, especially aluminium salts, should contraindicate use.
• History of severe allergic reaction to a previous hepatitis B vaccine dose requires evaluation.
• Moderate or severe acute illness with fever may warrant postponement of vaccination.
• Pregnancy and lactation status should be assessed; vaccination may be given if benefits outweigh risks.
• Immunocompromised individuals may have a reduced immune response and should follow recommended dosing schedules.
• Use caution in patients with chronic kidney disease due to aluminium exposure.

Hbvaxpro does not have many documented drug‑drug interactions, but certain agents may influence vaccine response or safety.

Avoid

• Concurrent administration of other live vaccines at the same anatomical site.
• Use of systemic corticosteroids or immunosuppressive therapy at high doses during the vaccination period.

Use with caution

• Antiviral therapy for hepatitis B infection; timing may be coordinated with the provider.
• Blood products or immunoglobulins given within 4 weeks before or after vaccination may reduce immunogenicity.
• Chronic alcohol use or heavy smoking, which can impair immune response.